Jci_page_head_homepage_01 Jci_page_head_homepage_02
R. Gisli Jenkins, Xiao Su, George Su, Christopher J. Scotton, Eric Camerer, Geoffrey J. Laurent, George E. Davis, Rachel C. Chambers, Michael A. Matthay, Dean Sheppard
Published in Volume 116, Issue 6
J Clin Invest. 2006; 116(6):1606–1614 doi:10.1172/JCI27183
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 3
PAR1 agonists lead to a time-dependent increase in Smad2 phosphorylation that is αv β6 integrin dependent, but independent of new protein synthesis.

(A and B) The time course of Smad2 phosphorylation in response to 10 μM PAR1-activating peptide SFLLRN (A) and 10 nM thrombin (B), in the presence or absence of an αvβ6 blocking antibody, was assessed by immunoblotting. Total Smad2 levels over time and in response to the αvβ6 blocking antibody were assessed as control. (C) Immunoblot showing the effect of the protein synthesis inhibitor cycloheximide (CHX) on SFLLRN-induced Smad2 phosphorylation. The effectiveness of cycloheximide as a protein synthesis inhibitor was determined by immunoblotting for total Smad2, and immunoblotting for MyD88 was used as a loading control.